Abstract & Details
Description
Award ID: 2330736
The broader impact of this Small Business Innovation Research (SBIR) Phase II project is on the mitigation of the worldwide counterfeit drug market which has a significant impact on public health, brand integrity, and revenue. Specifically, this project aims to develop a state of the art, counterfeit-proof, ID security technology that enables vaccine and biologic manufacturers to tag, track, and authenticate its products throughout the supply chain. The technology involves a scalable manufacturing process that imprints a covert and highly encrypted pattern onto a label that may be placed on individual vaccine vials. The imprinted pattern produces an image that may only be read with a proprietary interrogation process. Additionally, each label incorporates a serialized code. The focus of this serialization is to provide each dose, each vial, with its own unique signature or fingerprint. The serialization aspect of the labels is significant for vaccine/biologic manufacturers, as this enables traceability of dosage form throughout the supply chain, a mandate required by global regulatory agencies. The proposed project aims to provide both the pharma industry and the global health community with tagging technology that ensures supply chain integrity for drug products throughout the world. Specifically, the focus of the Phase II effort is to: 1) demonstrate the scalable production of computationally designed tags, 2) integrate an automated tagging and reading process directly with a drug product manufacturing line, and 3) demonstrate the production and use of a handheld reader that enables authentication of product at any point in the supply chain. An ID technology that differentiates authentic from counterfeit products is anticipated at the conclusion of the effort. The authentication process will reveal product composition, origin of manufacture, date of manufacture, expiration, and other pertinent information. The labels will withstand temperatures typically encountered during storage and will also incorporate various degrees of tamper evident and tamper proof characteristics. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
NSF Program Director: Erik Pierstorff
The broader impact of this Small Business Innovation Research (SBIR) Phase II project is on the mitigation of the worldwide counterfeit drug market which has a significant impact on public health, brand integrity, and revenue. Specifically, this project aims to develop a state of the art, counterfeit-proof, ID security technology that enables vaccine and biologic manufacturers to tag, track, and authenticate its products throughout the supply chain. The technology involves a scalable manufacturing process that imprints a covert and highly encrypted pattern onto a label that may be placed on individual vaccine vials. The imprinted pattern produces an image that may only be read with a proprietary interrogation process. Additionally, each label incorporates a serialized code. The focus of this serialization is to provide each dose, each vial, with its own unique signature or fingerprint. The serialization aspect of the labels is significant for vaccine/biologic manufacturers, as this enables traceability of dosage form throughout the supply chain, a mandate required by global regulatory agencies. The proposed project aims to provide both the pharma industry and the global health community with tagging technology that ensures supply chain integrity for drug products throughout the world. Specifically, the focus of the Phase II effort is to: 1) demonstrate the scalable production of computationally designed tags, 2) integrate an automated tagging and reading process directly with a drug product manufacturing line, and 3) demonstrate the production and use of a handheld reader that enables authentication of product at any point in the supply chain. An ID technology that differentiates authentic from counterfeit products is anticipated at the conclusion of the effort. The authentication process will reveal product composition, origin of manufacture, date of manufacture, expiration, and other pertinent information. The labels will withstand temperatures typically encountered during storage and will also incorporate various degrees of tamper evident and tamper proof characteristics. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
NSF Program Director: Erik Pierstorff
| Status | Active |
|---|---|
| Effective start/end date | 06/15/24 → 05/31/27 |
Funding
- SBIR Phase II: $951,394.00
Active Fiscal Year
- FY2024
- FY2027
- FY2026
- FY2025
Start Fiscal Year
- FY2024
TIP Programs
- SBIR Phase II
Small Business
- Yes
Key Technology Areas
- Biotechnology
- (confidence score: 100%)
- Robotics and Advanced Manufacturing
- (confidence score: 98%)
Technology Foci
- Synthetic Biology
- (confidence score: 99%)
- Medical Technology
- (confidence score: 100%)
- Bio-manufacturing
- (confidence score: 100%)
- Robotics and Advanced Manufacturing (Broad)
- (confidence score: 100%)
Congressional District at Award
- District n. 00 of Delaware
Current Congressional District
- District n. 00 of Delaware
United States
- Delaware
Core Based Statistical Area (CBSA)
- Philadelphia-Camden-Wilmington, PA-NJ-DE-MD
County
- County: New Castle, DE
EPSCoR Jurisdiction
- Yes
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint. Learn more about Elsevier's Fingerprint Engine here: https://beta.elsevier.com/products/elsevier-fingerprint-engine